PTGS2: Cyclooxygenase-2
Protein in Canis lupus familiaris that 5 drugs act on.
- Drugs that act on it: 5
- Approved: 0
- In phases 1 to 3: 4
- Sponsors: 0
Who is on it, and how far along
Every drug ChEMBL records acting on PTGS2, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 5
Approved0
Phase 30
Phase 24
Phase 10
Preclinical or unknown1
The landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Cyclooxygenase-2 inhibitor.| Firocoxib | Phase 2 | — | Small molecule | Inhibitor | 0 |
| Mavacoxib | Phase 2 | — | Small molecule | Inhibitor | 0 |
| Robenacoxib | Phase 2 | — | Small molecule | Inhibitor | 0 |
| Tepoxalin | Phase 2 | — | Small molecule | Inhibitor | 0 |
| Enflicoxib | Preclinical or unknown | — | Small molecule | Inhibitor | 0 |
Genes and related targets
Complexes and families that share a gene with this target- Genes
- PTGS2
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4033, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. ChEMBL and Open Targets